India's first indigenous H5N1 bird flu vaccine launched in Bhopal at ₹1–2 per dose
Synopsis
Key Takeaways
Union Agriculture Minister Shivraj Singh Chouhan on 20 November 2026 launched India's first indigenous vaccine against H5N1 bird flu in Bhopal, marking a significant milestone in the country's animal disease management programme. The vaccine was developed by scientists at the National Institute of High Security Animal Diseases (NIHSAD), which functions under the Indian Council of Agricultural Research (ICAR).
A World First, at ₹1–2 a Dose
Chouhan described the vaccine as the world's first against this particular variant of H5N1 bird flu, adding that its pricing — between ₹1 and ₹2 per dose — has been deliberately kept within reach of small and marginal poultry farmers. 'The vaccine will cost only Rs 1 to Rs 2 per dose, so that even small poultry farmers can afford it. Animals are moving ATMs for farmers, providing them with a regular source of income,' the Minister said while formally dedicating the vaccine to the nation.
Chouhan also revealed that he chose Bhopal over New Delhi as the launch venue specifically so the scientists who developed the vaccine could be present at the event — an acknowledgement of the team's months of continuous work under stringent biosafety protocols.
Scale of Bird Flu Devastation in India
India has recorded more than 500 bird flu outbreaks since the first was detected in Navapur, Maharashtra in 2006, during which around 10 lakh chickens died and several more were culled. Subsequent outbreaks have continued to inflict heavy losses: approximately nine lakh chickens perished during a 2021 outbreak, while two lakh more died in the current year, according to the Minister. Beyond the immediate toll on birds, Chouhan cautioned that recurring H5N1 outbreaks also carry a potential risk of transmission to mammals and humans.
Broader Cost of Animal Diseases to India
Chouhan placed the H5N1 vaccine launch within a wider context of livestock disease burden, citing estimated annual losses of roughly ₹56,000 crore across animal illnesses. This includes ₹22,000 crore attributed to foot-and-mouth disease, ₹20,000 crore from lumpy skin disease, ₹9,212 crore from brucellosis, and ₹4,683 crore from Peste des Petits Ruminants (PPR). The Minister noted that indigenous vaccines have already been developed against lumpy skin disease, classical swine fever, and African swine fever, with the H5N1 vaccine adding to this growing portfolio.
Under the National Animal Disease Control Programme, launched by Prime Minister Narendra Modi from Mathura, a total of 147.16 crore free doses have been administered against foot-and-mouth disease to date.
New ₹300 Crore Laboratory Announced for Bhopal
In a parallel announcement, Chouhan said a new state-of-the-art laboratory would be established in Bhopal at a cost of ₹300 crore, signalling a continued federal investment in the city as a hub for high-security animal disease research.
Scientists Behind the Breakthrough
Eight scientists were formally acknowledged at the event for their contributions to the research, including Dr S. Nagarajan, Dr Manoj Kumar, and Dr Aniket Sanyal. Chouhan praised the team for working through weekends over several months and adhering to the strictest laboratory biosafety standards. 'Our scientists have once again demonstrated India's scientific capabilities. Those who go abroad and question the country's institutions and scientists should see the achievements of today's self-reliant India,' he said.
With the vaccine now formally launched, the focus will shift to production scale-up, regulatory clearances for commercial deployment, and integration into existing poultry disease control frameworks — steps that will determine how quickly small farmers see relief from H5N1-related losses.